The state-of-the-art immunosuppression drugs do not ensure indefi nite transplant survival,and most transplants are continuously lost to chronic rejection even years posttransplantation.This form of rejection is respo...The state-of-the-art immunosuppression drugs do not ensure indefi nite transplant survival,and most transplants are continuously lost to chronic rejection even years posttransplantation.This form of rejection is responsible for long-term failure of transplanted organs.The mechanisms involved in development of chronic rejection are not well-understood.One of the main features of chronic rejection is progressive luminal narrowing of graft vessels,which results in compromised blood flow,ischemia,cell death,and finally graft failure.All the existing immunosuppressive regimens are targeting acute rejection,and at present there is no available therapy for prevention of chronic rejection.Chronic rejection involves two major,but interrelated responses:The first is the host immune response against the transplant mediated primarily by alloreactive T and B cells,and the second is injury and repair of the graft(vasculopathy of graft vessels).Here we focus on recent advances in understanding the cellular and molecular aspects of chronic transplant vasculopathy and function of macrophages,topics pivotal for development of novel antichronic rejection therapies.展开更多
文摘The state-of-the-art immunosuppression drugs do not ensure indefi nite transplant survival,and most transplants are continuously lost to chronic rejection even years posttransplantation.This form of rejection is responsible for long-term failure of transplanted organs.The mechanisms involved in development of chronic rejection are not well-understood.One of the main features of chronic rejection is progressive luminal narrowing of graft vessels,which results in compromised blood flow,ischemia,cell death,and finally graft failure.All the existing immunosuppressive regimens are targeting acute rejection,and at present there is no available therapy for prevention of chronic rejection.Chronic rejection involves two major,but interrelated responses:The first is the host immune response against the transplant mediated primarily by alloreactive T and B cells,and the second is injury and repair of the graft(vasculopathy of graft vessels).Here we focus on recent advances in understanding the cellular and molecular aspects of chronic transplant vasculopathy and function of macrophages,topics pivotal for development of novel antichronic rejection therapies.
